Prodapt Joins the MuleSoft Technology Partner Program
14.9.2022 14:50:00 EEST | Business Wire | Press release
Prodapt today announced it has joined the MuleSoft Technology Partner Program and has contributed to the partner ecosystem by releasing a “MuleSoft Certified Connector for Aria”. The "Aria connector" accessible in Anypoint Exchange will allow companies to simplify integration to Aria and expose convenient methods for taking full advantage of the capabilities of Aria’s Billing and Monetization Platform.
Prodapt is helping its customers integrate Salesforce and Aria faster by using this Anypoint connector. It helps configure and expedite:
- Synch Account Info, Product Info, Billing & Invoice related Info b/w Salesforce and Aria
- Simplified authentication and easily adaptable to new changes
- Speed up the integration by 5x, enable customers to view their billing, invoice, and charges in real-time and improve customer satisfaction.
“As enterprises globally see exceptional value in building IT ecosystems using best-of-breed cloud applications, minimizing and simplifying integration costs using tried and tested best practices are critical for time-to-market and assurance. Prodapt’s MuleSoft Certified Connector for Aria adds to this maturing and growing ecosystem, to significantly simplify integration,” said Brendan O’Brien, Chief Innovation Officer, and Co-Founder, Aria Systems.
“Industries are facing new demands that push them to accelerate the pace of digital transformation,” said Brian Miller, senior vice president of business development, MuleSoft. “The Connectivity Benchmark Report shows that integration challenges are slowing down critical digital initiatives for 88% of organizations. This collaboration allows our mutual customers to create a composable enterprise by securely unlocking and integrating their data and apps to deliver new levels of speed, agility, and efficiency.”
The MuleSoft Technology Partner Program includes leading enterprise software companies across functional applications, such as CRM, enterprise resource planning (ERP), marketing automation, and HCM, as well as across industries, including financial services, healthcare, retail and media, and telecom. Using MuleSoft, technology partners help customers achieve greater speed, agility, and efficiency. MuleSoft’s platform enables companies to become composable businesses, where they can turn every asset in their organization — data, bots, and applications — into reusable building blocks to scale and increase the speed of work.
MuleSoft customers can learn more about Prodapt’s MuleSoft Certified Connector for Aria by visiting: https://www.mulesoft.com/exchange/com.mulesoft.connectors/mule-aria-crescendo-connector/
Prodapt customers can learn more about how to integrate data from siloed apps and systems faster and automate complete workflows more efficiently with MuleSoft at: https://www.mulesoft.com/platform/enterprise-integration.
About Prodapt
Prodapt has a singular focus on the Connectedness vertical. Prodapt partners with the leading creators of our hyper-connected world. Prodapt’s customers range from telecom operators, digital/multi-service providers (D/MSPs), technology and digital platform companies in the business of Connectedness.
Prodapt builds, integrates, and operates solutions enabling next-generation technologies and innovations. Prodapt services global leaders including Google, Facebook, Amazon, Microsoft, AT&T, Verizon, CenturyLink, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, Deutsche Telekom, among many others. Prodapt’s customers help more than a billion people, and five billion devices stay connected.
Prodapt has offices in North America, Europe, Latam, India, and Africa. It is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
Salesforce and others are among the trademarks of salesforce.com, inc.
MuleSoft is a registered trademark of MuleSoft, Inc., a Salesforce company. All other marks are those of respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005494/en/
Contact information
Manian Sivaramakrishnan,
Head - Enterprise Marketing
maniannagasubra.s@prodapt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom